Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus
Autore:
Nyholm, B; Brock, B; Orskov, L; Schmitz, O;
Indirizzi:
Aarhus Univ Hosp, Aarhus Kommune Hosp, Dept Med Endocrinol & Diabet, DK-8000 Aarhus, Denmark Aarhus Univ Hosp Aarhus Denmark DK-8000 Diabet, DK-8000 Aarhus, Denmark Univ Aarhus, Dept Clin Pharmacol, Aarhus, Denmark Univ Aarhus Aarhus Denmark Aarhus, Dept Clin Pharmacol, Aarhus, Denmark Aalborg Sygehus N, Dept Endocrinol, Aalborg, Denmark Aalborg Sygehus N Aalborg Denmark N, Dept Endocrinol, Aalborg, Denmark
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 9, volume: 10, anno: 2001,
pagine: 1641 - 1652
SICI:
1354-3784(200109)10:9<1641:ARAANP>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
ISLET-AMYLOID POLYPEPTIDE; PLASMA-GLUCOSE PROFILES; GENE-RELATED PEPTIDE; CALCITONIN-RECEPTOR; POSTPRANDIAL HYPERGLYCEMIA; ANALOG PRAMLINTIDE; RESISTANCE INVIVO; SKELETAL-MUSCLE; DOSE-RESPONSES; BINDING-SITES;
Keywords:
amylin; beta-cell deficiency; diabetes mellitus; gastric emptying; glucagon; glycaemic control; insulin; postprandial hyperglycaemia; pramlintide;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
100
Recensione:
Indirizzi per estratti:
Indirizzo: Schmitz, O Aarhus Univ Hosp, Aarhus Kommune Hosp, Dept Med Endocrinol & Diabet M, DK-8000 Aarhus, Denmark Aarhus Univ Hosp Aarhus Denmark DK-8000 -8000 Aarhus, Denmark
Citazione:
B. Nyholm et al., "Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus", EXPERT OP I, 10(9), 2001, pp. 1641-1652

Abstract

Amylin is a peptide hormone which is co-secreted with insulin from the pancreatic beta-cell. Type 1 diabetic individuals and some Type 2 diabetic individuals are characterised by amylin deficiency. Animal experiments have revealed several actions of amylin on intermediary metabolism, of these some have been demonstrated to be of potential physiological relevance in humans. In particular amylin appears to have important actions in controlling prandial glucose homeostasis. The peptide hormone inhibits postprandial glucagon secretion and delays gastric emptying thereby modifying postprandial hyperglycaemia in diabetic individuals which presumably adds to overall glycaemic control without a concomitant increase in the number of severe hypoglycaemic episodes. Moreover, amylin acts as a satiety agent. Amylin replacement may therefore improve glycaemic control in diabetes mellitus. However, human amylin exhibits physicochemical properties predisposing the peptide hormone to aggregate and form amyloid fibres, which makes it unsuitable for pharmacological use. A stable analogue, pramlintide, with actions and pharmacokinetic and pharmacodynamic properties similar to the native peptide has therefore been developed. The efficacy and safety of pramlintide administration to diabetic individuals have been tested in a large number of clinical trials. It is the aim of this review to describe possible (patho)physiological actions of amylin as demonstrated in animal and human models, to discuss the background for potential amylin (analogue) replacement in diabetes mellitus and to review results from clinical trials with the amylin receptor analogue pramlintide.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:07:17